Rituximab maintenance for relapsed refractory thrombotic thrombocytopenic purpura
Bhagirath VC et al. – Clinical and laboratory remission were achieved after one dose of rituximab, with normalization of ADAMTS13 activity and disappearance of ADAMTS13 inhibitor. Three subsequent doses of rituximab were given without incident and the patient remained in remission after 3.5years of follow–up. Maintenance dosing of rituximab should be considered in some patients with relapsing thrombotic thrombocytopenic purpura (TTP).